/Companies

VirTech Bio

Beverly, US · Founded 2013 · Delaware corporation

Find your way into VirTech Bio

Sign up to see every warm intro you have to VirTech Bio

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the VirTech Bio team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

VirTech Bio develops OxyBridge, a human-derived hemoglobin-based oxygen carrier (HBOC) intended as a blood substitute for time-critical trauma patients in hemorrhagic shock and for pre-transplant donor organ perfusion. The product is aimed at military and civilian trauma care and organ transplantation, using an ultra-polymer design to deliver oxygen and maintain blood pressure without refrigeration.

Founders & leadership

JT
Joseph TuckerExecutive
MVMatias Vidal
Matias VidalCo-Founder & Executive Chairman
DHDallas Hack
Dallas HackCEO & Director, Medical Affairs
CDCOL(R) Dallas Hack, MD, MPH
COL(R) Dallas Hack, MD, MPHCEO & Director, Medical AffairsA retired Army colonel and physician, he directed the Combat Casualty Care Research Program at the US Army Medical Research and Materiel Command from 2008 to 2014 and later coordinated its Brain Health/Fitness Research Program, after serving as Command Surgeon for Multinational Force Iraq and Chief of Preventive Medicine Service at Walter Reed Army Medical Center. He has worked as an independent brain health consultant since 2015 and completed the I-Corps @ NIH program in 2019.

Reported raises · per SEC filings

Form D private placements

$500K disclosed across 1 round · 2016

▶$500KraisedJun 2016 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Joseph TuckerExecutive Officer
  • Matias VidalExecutive Officer, Director
Offering amount
$500K
Amount sold
$500K
Minimum investment
$50K
First sale
Jun 2016
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 2

Companies working in the same space as VirTech Bio.

Non-dilutive funding · 3 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
Department of DefenseSpecial Operations CommandPhase II2018$1.8M
Department of DefenseSpecial Operations CommandPhase I2018$148.1K
National Institutes of Health (NIH)National Institutes of HealthPhase I2016$239K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Frequently asked questions

What does VirTech Bio do?
VirTech Bio develops OxyBridge, a human-derived hemoglobin-based oxygen carrier (HBOC) intended as a blood substitute for time-critical trauma patients in hemorrhagic shock and for pre-transplant donor organ perfusion. The product is aimed at military and civilian trauma care and organ transplantation, using an ultra-polymer design to deliver oxygen and maintain blood pressure without refrigeration.
How much funding has VirTech Bio raised?
VirTech Bio has disclosed $500K raised across 1 round.
Where is VirTech Bio headquartered?
VirTech Bio is headquartered in Beverly, US.